Edesa Biotech
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 16
- Market Cap
- -
- Website
- http://www.edesabiotech.com
- Introduction
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.
Edesa Biotech Advances Vitiligo Treatment Program, Secures $15M Funding for EB06 Development
• Edesa Biotech is preparing to submit regulatory data to FDA for EB06, an anti-CXCL10 monoclonal antibody targeting vitiligo, with submissions planned for mid-2025.
• The company secured $15 million in gross proceeds through a private placement, strengthening its position to advance the vitiligo program through clinical development.
• Phase 2 clinical trial for moderate-to-severe nonsegmental vitiligo patients is anticipated to deliver topline results within 12-18 months after FDA clearance.
© Copyright 2025. All Rights Reserved by MedPath